Schedule-Dependent Synergy Between the Histone Deacetylase Inhibitor Belinostat and the Dihydrofolate Reductase Inhibitor Pralatrexate in T-and B-cell Lymphoma Cells in vitro

Pralatrexate (Folotyn; PLX) and belinostat (Beleodaq; BLS) are registered for the treatment of patients with peripheral T-cell lymphoma (PTCL) and are being considered for other lymphomas. In this study we investigated whether BLS had the ability to potentiate the cytotoxicity of PLX. A panel of lym...

Descripción completa

Detalles Bibliográficos
Autores principales: Peters, Godefridus J., van Gemert, Frank P. A., Kathmann, Ietje, Reddy, Guru, Cillessen, Saskia A. G. M., Jansen, Gerrit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581941/
https://www.ncbi.nlm.nih.gov/pubmed/33163492
http://dx.doi.org/10.3389/fcell.2020.577215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581941/
https://www.ncbi.nlm.nih.gov/pubmed/33163492
http://dx.doi.org/10.3389/fcell.2020.577215

Ejemplares similares